Because the development and progression of prostate cancer (PCa) depends on AR signaling, inhibition of AR signaling by androgen deprivation therapy (ADT) (e.g., luteinizing hormone-agonist/antagonist with or without casodex) is the mainstay of treatment for advanced castration-sensitive PCa (CSPC). This evidence concerns the gene AR and prostate carcinoma.